🚨 Eli Lilly slips as generic weight-loss drugs flood India; Novo Nordisk holds firm #EliLilly #NovoNordisk #WeightLossDrugs

Wegovy High-Dose Priced $50 Below Zepbound Novo Nordisk priced high-dose Wegovy $50 below Eli Lilly's Zepbound on Apr 8, 2026; the pricing move will influence payer negotiations and formulary placement in the GLP-1 class.

Wegovy High-Dose Priced $50 Below Zepbound: Novo Nordisk priced high-dose Wegovy $50 below Eli Lilly's Zepbound on Apr 8, 2026; the pricing move will influence payer negotiations and formulary placement in the GLP-1 class. 👈 Read full analysis #Wegovy #Zepbound #NovoNordisk #ELiLilly #GLP1

Eli Lilly Rises After Cramer Endorses New Deal LLY shares rose ~2.6% on Apr 4, 2026 after Jim Cramer praised a new deal (Yahoo Finance Apr 4, 2026); institutional investors should await primary filings before revising allocations.

Eli Lilly Rises After Cramer Endorses New Deal: LLY shares rose ~2.6% on Apr 4, 2026 after Jim Cramer praised a new deal (Yahoo Finance Apr 4, 2026); institutional investors should await primary filings before revising… 👈 Read full analysis #EliLilly #LLY #JimCramer #StockMarket #Investing

FDA aprueba píldora de Eli Lilly para obesidad en tiempo récord La FDA aprobó una nueva píldora tipo GLP-1 para tratar la obesidad, desarrollada por Eli Lilly. El fármaco recibió autorización en solo 50 días, convirtiéndose en el proceso de aprobación más rápido p...

¡Avance histórico! La FDA aprueba en récord de 50 días la píldora GLP-1 de Eli Lilly para tratar la obesidad, el proceso más rápido de su clase. Un gran paso contra el sobrepeso.

twuai.com/search/HUTEz... #noticiasnmásunivision #obesidad #EliLilly

Acquisitions: #FifthThirdBancorp > #Comerica

Agreed Acquisitions: #Biogen > #ApellisPharmaceuticals; #EliLilly > #CentessaPharmaceuticals; #Novartis > #Excellergy; #Sysco > #RestaurantDepot; #Uber > #Blacklane

SPAC: #IQMQuantumComputers

Closure: #Yupp

Gespot op donderdag 2 april 2026

Eli Lilly’s afslankpil: revolutie binnen een revolutie
www.foodlog.nl/gespot/2026-...
#gezondheid #elililly #orforglipron #glp1 #afslankmiddelen #afslankpil

Eli Lilly Launches Zepbound KwikPen on Ro Eli Lilly added Zepbound KwikPen to Ro on Apr 2, 2026; the tirzepatide pen (FDA approved Nov 17, 2023) expands telehealth distribution and tests payer adjudication.

Eli Lilly Launches Zepbound KwikPen on Ro: Eli Lilly added Zepbound KwikPen to Ro on Apr 2, 2026; the tirzepatide pen (FDA approved Nov 17, 2023) expands telehealth distribution and tests payer adjudication. 👈 Read full analysis #EliLilly #Zepbound #KwikPen #Tirzepatide #Telehealth

#trends today for 'bbc breakfast' 'eli lilly' & 'police arrest'

Click/Tap below:

www.newsmason.com?query=%22bbc...

www.newsmason.com?query=%22eli...

www.newsmason.com?query=%22pol...

#bbcbreakfast #elililly #policearrest

FDA grants speedy approval to Eli Lilly weight-loss pill - Replaye The Federal Drug Administration (FDA) has approved a new once-daily weight-loss pill from Eli Lilly, adding to the bevy of GLP-1 medications available in the consumer marketplace. The drug manufacture...

FDA grants speedy approval to Eli Lilly weight-loss pill
replaye.com/fda-grants-s...

#News #FDA #EliLilly #WeightLoss #Drugs

Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says - Replaye Eli Lilly opposes the White House's push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said in an interview with CNBC.

Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says
replaye.com/eli-lilly-op...

#News #EliLilly #Trump #DonaldTrump #Drugs

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market - Replaye The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
replaye.com/fda-approves...

#News #FDA #EliLilly #GLP1 #WeightLoss

Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

#EliLilly has claimed US approval for oral GLP-1 agonist #orforglipron (under the name #Foundayo) setting up a market clash with #NovoNordisk 's first-to-market #Wegovy pill.

Eli Lilly's Foundayo is under investigation for potential links to thyroid tumors, including cancer. The drug's safety profile for pediatric patients remains unconfirmed. #EliLilly #HealthSafety

Lilly to Buy Centessa for OX2R Sleep Drugs Eli Lilly announced acquisition of Centessa on Mar 31, 2026 (Investing.com). Narcolepsy prevalence estimated at ~0.05%; deal terms pending disclosure.

Lilly to Buy Centessa for OX2R Sleep Drugs: Eli Lilly announced acquisition of Centessa on Mar 31, 2026 (Investing.com). Narcolepsy prevalence estimated at ~0.05%; deal terms pending disclosure. 👈 Read full analysis #EliLilly #Centessa #SleepDrugs #Narcolepsy #OX2R

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly - Replaye Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as much as $600 a year on the pill.

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
replaye.com/novo-nordisk...

#News #NovoNordisk #Wegovy #ObesityDrugs #Drugs #EliLilly

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs - Replaye Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake.

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
replaye.com/lilly-to-spe...

#News #EliLilly #Centessa #Sleep #Drugs #Health

NICE to reconsider two Alzheimer’s drugs, following manufacturers' appeal Two pioneering drugs that treat the underlying causes of Alzheimer's disease are to be reconsidered by NICE.

NICE to reconsider two Alzheimer’s drugs, following manufacturers' appeal

Read it here 👉️ buff.ly/Yz91dLW

#alzheimers #NICE #drug #appeal #Eisai #EliLilly

Lilly Acquires Centessa for Up to $7.8B Eli Lilly agreed to buy Centessa for up to $7.8bn (announced Mar 31, 2026), targeting experimental narcolepsy drugs for a condition affecting ~0.05% of the population.

Lilly Acquires Centessa for Up to $7.8B: Eli Lilly agreed to buy Centessa for up to $7.8bn (announced Mar 31, 2026), targeting experimental narcolepsy drugs for a condition affecting ~0.05% of the population. 👈 Read full analysis #EliLilly #Centessa #PharmaNews #Biotech #Narcolepsy

Article image

Eli Lilly bets big on sleep with its $7.8B Centessa acquisition! A major move into a growing market. But will it be enough to drive long-term growth? #Pharma #Investing #EliLilly #PanicPortfolio

Article image

Eli Lilly punta sul sonno con l'acquisizione da 7,8 miliardi di Centessa! Un ingresso importante in un mercato in crescita. Ma sarà sufficiente a sostenere la crescita a lungo termine? #Farmaceutico #Investimenti #EliLilly #CapitaleEmotivo

Eli Lilly makes $7.8bn takeover play for Centessa Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

#CentessaPharma is heading for an #acquisition by #EliLilly, which has offered $6.3 billion for the company, with another $1.5 billion in future payments tied to #FDA approvals of its lead drug for #sleepdisorders.

Eli Lilly Buys Centessa for $6.3B to Bolster Sleep Drugs Eli Lilly agreed to buy Centessa for $6.3bn on Mar 31, 2026, expanding its sleep-medicine pipeline and signaling continued program-focused M&A in pharma.

Eli Lilly Buys Centessa for $6.3B to Bolster Sleep Drugs: Eli Lilly agreed to buy Centessa for $6.3bn on Mar 31, 2026, expanding its sleep-medicine pipeline and signaling continued program-focused M&A in… 👈 Read full analysis #EliLilly #Centessa #PharmaMergers #SleepMedicine #HealthcareInnovation

Centessa Soars on $6.3bn Lilly Takeover Eli Lilly offered $6.3bn for Centessa on Mar 31, 2026, triggering a sharp re-rating; deal sets a new benchmark for mid-cap biotech exits.

Centessa Soars on $6.3bn Lilly Takeover: Eli Lilly offered $6.3bn for Centessa on Mar 31, 2026, triggering a sharp re-rating; deal sets a new benchmark for mid-cap biotech exits. 👈 Read full analysis #Centessa #EliLilly #Biotech #MergersAndAcquisitions #FinanceNews

Mounjaro maker wants NHS drug price rises in return for more investment in UK US firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministers

#Mounjaro #NHSdrugpricerises #EliLilly #rebatescheme #Mounjaro #weightlossdrug #NHSdrugprices #NHSrebatescheme #antiobesitydrugs #NHScosteffectivenessthresholds #internationaldrugpricing #USUKdrugpricingdeal #brandedmedicines #obesity #obesitytreatment
zurl.co/6jNlv

Eli Lilly investeert 2,39 miljard euro in samenwerking voor AI-geneesmiddelenontwikkeling In het kort Eli Lilly en Insilico Medicine zijn een samenwerking aangegaan die zich richt op het ontwikkelen van medicijnen die volledig met behulp van artificiële intelligentie zijn ontworpen. De overeenkomst, met een waarde van maximaal 2,39 miljard euro, geeft Eli Lilly de exclusieve wereldwijde rechten om deze nieuwe geneesmiddelen te ontwikkelen en op de […] The post Eli Lilly investeert 2,39 miljard euro in samenwerking voor AI-geneesmiddelenontwikkeling appeared first on Newsmonkey.

Eli Lilly investeert 2,39 miljard euro in samenwerking voor AI-geneesmiddelenontwikkeling #EliLilly #AIGeneesmiddelen #Farmacie #Innovatie #Gezondheid

Insilico Medicine Announces Global R&D Collaboration with Lilly

#EliLilly is taking their weight loss drug money and partnering with #nvidia and #InsilicoMedicine to use an AI engine for designing new drugs.

I hope that humans are still required to sign off and be held accountable (as much as any multi-billion dollar corporation).

insilico.com/news/uiy12zc...

#EliLilly and #Insilico Medicine have signed a $2.75 billion deal to bring #AIdeveloped #drugs to the global market. The agreement includes upfront payments, milestone payments, and royalties, and builds on their existing collaboration.…

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market www.cnbc.com/2026/03/29/e... #pharmacology #drugs #pharma #elililly

Le géant pharmaceutique américain Eli Lilly conclut un accord pour accélérer la mise sur le marché de médicaments développés grâce à l’IA Principaux renseignements Eli Lilly, une grande entreprise pharmaceutique américaine, s’est associée à Insilico Medicine, une société de biotechnologie basée à Hong Kong, dans le cadre d’un accord de 2,75 milliards de dollars (environ 2,5 milliards d’euros). Cette collaboration vise à mettre sur le marché mondial des médicaments innovants développés grâce à l’intelligence artificielle. Insilico Medicine […]

Le géant pharmaceutique américain Eli Lilly conclut un accord pour accélérer la mise sur le marché de médicaments développés grâce à l’IA #EliLilly #IntelligenceArtificielle #Pharmaceutique #Biotechnologie #Médicaments

Amerikaanse farmareus Eli Lilly sluit akkoord om AI-medicijnen sneller op de markt te brengen Key takeaways Eli Lilly, een groot Amerikaans farmaceutisch bedrijf, is een samenwerking aangegaan met Insilico Medicine, een in Hongkong gevestigd biotechnologiebedrijf, in een deal ter waarde van 2,75 miljard dollar (ongeveer 2,5 miljard euro). Deze samenwerking heeft tot doel innovatieve geneesmiddelen die zijn ontwikkeld met behulp van artificiële intelligentie op de wereldmarkt te brengen. Insilico […]

Amerikaanse farmareus Eli Lilly sluit akkoord om AI-medicijnen sneller op de markt te brengen #EliLilly #AIGeneesmiddelen #Farmacie #Innovatie #Gezondheidszorg